Harvard Bioscience (HBIO) Non-Current Assets (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Non-Current Assets data on file, last reported at $30.5 million in Q1 2026.

• Quarterly Non-Current Assets fell 12.72% year-over-year to $30.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $134.7 million (down 53.05% YoY) and the FY2025 annual result came in at $19.4 million, down 12.61% from the prior year.
• Non-Current Assets advanced to $30.5 million in Q1 2026 per HBIO's latest filing, from $19.4 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $98.8 million in Q2 2022 and bottomed at $19.4 million in Q4 2025.
• The 5-year median for Non-Current Assets is $82.5 million (2024), against an average of $61.6 million.
• The widest annual swing landed in 2022, when Non-Current Assets decreased 1.63%; it then tumbled 59.52% in 2025.
• Tracing HBIO's Non-Current Assets over 5 years: stood at $30.0 million in 2022, then decreased by 17.98% to $24.6 million in 2023, then slipped by 9.8% to $22.2 million in 2024, then fell by 12.61% to $19.4 million in 2025, then surged by 57.18% to $30.5 million in 2026.
• Per Business Quant, the three latest HBIO Non-Current Assets figures stand at $30.5 million (Q1 2026), $19.4 million (Q4 2025), and $34.2 million (Q3 2025).

Peer Comparison